National Heart, Lung, and Blood Institute; Notice of Closed Meetings, 55557 [2018-24222]
Download as PDF
<![CDATA[
Federal Register / Vol. 83, No. 215 / Tuesday, November 6, 2018 / Notices
The National Heart, Lung and
Blood Institute (NHLBI), National
Institutes of Health, Department of
Health and Human Services, is
contemplating the grant of an exclusive
commercialization patent license to
Ovensa, Inc. headquartered in Ontario,
Canada, to practice the inventions
embodied in the patent application(s)
listed in the Supplementary Information
section of this notice.
DATES: Only written comments and/or
applications for a license which are
received by the NHLBI Office of
Technology Transfer and Development
November 21, 2018 will be considered.
ADDRESSES: Requests for copies of the
patent applications, inquiries, and
comments relating to the contemplated
exclusive patent license should be
directed to: Michael Shmilovich, Esq.,
Senior Licensing and Patent Manager,
31 Center Drive, Room 4A29, MSC2479,
Bethesda, MD 20892–2479, phone
number 301–435–5019, or shmilovm@
mail.nih.gov.
SUPPLEMENTARY INFORMATION: The
following and all continuing U.S. and
foreign patents/patent applications
thereof are the intellectual properties to
be licensed under the prospective
agreement to Ovensa: HHS Ref. No. E–
103–2013–0, U.S. Provisional Patent
Application 61/839,239, ‘‘GlucanEncapsulated siRNA For Treating Type
2 Diabetes Mellitus,’’ filed June 25,
2013, International Patent Application
PCT/2014/043924 filed June 24, 2014,
European Patent Application
14818342.9 filed June 24, 2018, and US
Patent 10,077,446 filed June 24, 2014
and issued September 18, 2018. The
patent rights in this invention have been
assigned to the Government of the
United States of America. The
prospective license would be granted
worldwide and in a field of use not
broader than therapeutics for preventing
or treating insulin resistance and nonalcoholic fatty liver disease/nonalcoholic steatohepatitis. The scope of
any proposed licensed may also be
limited to products sold that include
therapeutic siRNAs encapsulated in
nanoparticles made from either glucan
based biopolymers and/or Ovensa’s
TRIOZANTM (N,N,N-Trimethyl
Chitosan) proprietary biopolymer.
The invention pertains to the use of
glucan encapsulated nonimmunostimulatory small interfering
RNAs (siRNAs) to treat type-2 diabetes.
Endocannabinoids (EC) are lipid
signaling molecules that act on the same
cannabinoid receptors that recognize
and mediate the effects of endo- and
phytocannabanoids. EC receptor CB1R
activation is implicated in the
khammond on DSK30JT082PROD with NOTICES
SUMMARY:
VerDate Sep<11>2014
17:05 Nov 05, 2018
Jkt 247001
development of obesity and its
metabolic consequences, including
insulin resistance and type 2 diabetes.
Beta-cell loss has been demonstrated in
a Zucker diabetic fatty (ZDF) rat model
of type-2 diabetes through CB1Rmediated activation of a macrophagemediated inflammatory response.
Conversely, rats treated with a
peripheral CB1R antagonist restores
normoglycemia and preserves beta-cell
function. Similar results are seen
following selective in vivo knockdown
of macrophage CB1R by daily treatment
of ZDF rats with the instant D-glucanencapsulated CB1R small interfering
RNA (siRNA). Knock-down of CB1R
using glucan encapsulated siRNA
represent new methods of treating type2 diabetes or preventing the progression
of insulin resistance to overt diabetes.
This notice is made in accordance
with 35 U.S.C. 209 and 37 CFR part 404.
The prospective exclusive patent license
will be royalty bearing and may be
granted unless within fifteen (15) days
from the date of this published notice,
the NHLBI receives written evidence
and argument that establishes that the
grant of the license would not be
consistent with the requirements of 35
U.S.C. 209 and 37 CFR part 404.
Complete applications for a license in
the prospective field of use that are
timely filed in response to this notice
will be treated as objections to the grant
of the contemplated exclusive patent
license.
Comments and objections submitted
to this notice will not be made available
for public inspection and, to the extent
permitted by law, will not be released
under the Freedom of Information Act,
5 U.S.C. 552.
Dated: October 24, 2018.
Michael A. Shmilovich,
Senior Licensing and Patenting Manager,
National Heart, Lung, and Blood Institute,
Office of Technology Transfer and
Development.
[FR Doc. 2018–24225 Filed 11–5–18; 8:45 am]
BILLING CODE 4140–01–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
National Institutes of Health
National Heart, Lung, and Blood
Institute; Notice of Closed Meetings
Pursuant to section 10(d) of the
Federal Advisory Committee Act, as
amended, notice is hereby given of the
following meetings.
The meetings will be closed to the
public in accordance with the
provisions set forth in sections
PO 00000
Frm 00044
Fmt 4703
Sfmt 4703
55557
552b(c)(4) and 552b(c)(6), Title 5 U.S.C.,
as amended. The grant applications and
the discussions could disclose
confidential trade secrets or commercial
property such as patentable material,
and personal information concerning
individuals associated with the grant
applications, the disclosure of which
would constitute a clearly unwarranted
invasion of personal privacy.
Name of Committee: National Heart, Lung,
and Blood Institute Special Emphasis Panel
Review of NHLBI Cardiac Surgery Network
Coordinating Center.
Date: November 26, 2018.
Time: 1:00 p.m. to 3:00 p.m.
Agenda: To review and evaluate grant
applications.
Place: National Institutes of Health, 6701
Rockledge Drive, Bethesda, MD 20892
(Telephone Conference Call).
Contact Person: Shelley S Sehnert, Ph.D.,
Scientific Review Officer, Office of Scientific
Review/DERA, National Heart, Lung, and
Blood Institute, 6701 Rockledge Drive, Room
7206, Bethesda, MD 20892–7924, 301–435–
0303, ssehnert@nhlbi.nih.gov.
Name of Committee: National Heart, Lung,
and Blood Institute Special Emphasis Panel
NHLBI SBIR Phase IIB Bridge Awards.
Date: November 27, 2018.
Time: 7:30 a.m. to 9:30 a.m.
Agenda: To review and evaluate grant
applications.
Place: Crowne Plaza, Washington National
Airport, 1489 Jefferson Davis Hwy, Arlington,
VA 22202.
Contact Person: William J Johnson, Ph.D.,
Scientific Review Officer, Office of Scientific
Review/DERA, National Heart, Lung, and
Blood Institute, 6701 Rockledge Drive, Room
7178, Bethesda, MD 20892–7924, 301–827–
7938, johnsonwj@nhlbi.nih.gov.
Name of Committee: National Heart, Lung,
and Blood Institute Special Emphasis Panel
NHLBI SBIR Phase IIB Small Market Awards.
Date: November 27, 2018.
Time: 9:30 a.m. to 5:00 p.m.
Agenda: To review and evaluate grant
applications.
Place: Crowne Plaza, Washington National
Airport, 1489 Jefferson Davis Hwy, Arlington,
VA 22202.
Contact Person: William J Johnson, Ph.D.,
Scientific Review Officer, Office of Scientific
Review/DERA, National Heart, Lung, and
Blood Institute, 6701 Rockledge Drive, Room
7178, Bethesda, MD 20892–7924, 301–827–
7938, johnsonwj@nhlbi.nih.gov.
(Catalogue of Federal Domestic Assistance
Program Nos. 93.233, National Center for
Sleep Disorders Research; 93.837, Heart and
Vascular Diseases Research; 93.838, Lung
Diseases Research; 93.839, Blood Diseases
and Resources Research, National Institutes
of Health, HHS)
Dated: October 31, 2018.
Ronald J. Livingston, Jr.,
Program Analyst, Office of Federal Advisory
Committee Policy.
[FR Doc. 2018–24222 Filed 11–5–18; 8:45 am]
BILLING CODE 4140–01–P
E:\FR\FM\06NON1.SGM
06NON1
]]>Agencies
[Federal Register Volume 83, Number 215 (Tuesday, November 6, 2018)]
[Notices]
[Page 55557]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 2018-24222]
-----------------------------------------------------------------------
DEPARTMENT OF HEALTH AND HUMAN SERVICES
National Institutes of Health
National Heart, Lung, and Blood Institute; Notice of Closed
Meetings
Pursuant to section 10(d) of the Federal Advisory Committee Act, as
amended, notice is hereby given of the following meetings.
The meetings will be closed to the public in accordance with the
provisions set forth in sections 552b(c)(4) and 552b(c)(6), Title 5
U.S.C., as amended. The grant applications and the discussions could
disclose confidential trade secrets or commercial property such as
patentable material, and personal information concerning individuals
associated with the grant applications, the disclosure of which would
constitute a clearly unwarranted invasion of personal privacy.
Name of Committee: National Heart, Lung, and Blood Institute
Special Emphasis Panel Review of NHLBI Cardiac Surgery Network
Coordinating Center.
Date: November 26, 2018.
Time: 1:00 p.m. to 3:00 p.m.
Agenda: To review and evaluate grant applications.
Place: National Institutes of Health, 6701 Rockledge Drive,
Bethesda, MD 20892 (Telephone Conference Call).
Contact Person: Shelley S Sehnert, Ph.D., Scientific Review
Officer, Office of Scientific Review/DERA, National Heart, Lung, and
Blood Institute, 6701 Rockledge Drive, Room 7206, Bethesda, MD
20892-7924, 301-435-0303, [email protected].
Name of Committee: National Heart, Lung, and Blood Institute
Special Emphasis Panel NHLBI SBIR Phase IIB Bridge Awards.
Date: November 27, 2018.
Time: 7:30 a.m. to 9:30 a.m.
Agenda: To review and evaluate grant applications.
Place: Crowne Plaza, Washington National Airport, 1489 Jefferson
Davis Hwy, Arlington, VA 22202.
Contact Person: William J Johnson, Ph.D., Scientific Review
Officer, Office of Scientific Review/DERA, National Heart, Lung, and
Blood Institute, 6701 Rockledge Drive, Room 7178, Bethesda, MD
20892-7924, 301-827-7938, [email protected].
Name of Committee: National Heart, Lung, and Blood Institute
Special Emphasis Panel NHLBI SBIR Phase IIB Small Market Awards.
Date: November 27, 2018.
Time: 9:30 a.m. to 5:00 p.m.
Agenda: To review and evaluate grant applications.
Place: Crowne Plaza, Washington National Airport, 1489 Jefferson
Davis Hwy, Arlington, VA 22202.
Contact Person: William J Johnson, Ph.D., Scientific Review
Officer, Office of Scientific Review/DERA, National Heart, Lung, and
Blood Institute, 6701 Rockledge Drive, Room 7178, Bethesda, MD
20892-7924, 301-827-7938, [email protected].
(Catalogue of Federal Domestic Assistance Program Nos. 93.233,
National Center for Sleep Disorders Research; 93.837, Heart and
Vascular Diseases Research; 93.838, Lung Diseases Research; 93.839,
Blood Diseases and Resources Research, National Institutes of
Health, HHS)
Dated: October 31, 2018.
Ronald J. Livingston, Jr.,
Program Analyst, Office of Federal Advisory Committee Policy.
[FR Doc. 2018-24222 Filed 11-5-18; 8:45 am]
BILLING CODE 4140-01-P
